ClinicalTrials.gov
public full text
Public Domain
Does Varenicline Influence Alcohol Consumption in Alcohol Dependent Individuals?
The aim of the present clinical trial is to investigate whether 14 weeks of treatment with a prescription medication for smoking cessation (European trade name: Champix(R); US trade name: Chantix(R)), can reduce alcohol consumption in alcohol dependent individuals.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Study of Varencline Effects on Cigarette Smoking Reward and Craving During a Model of Brief Quit Attempt#1030434
- Efficacy of Varenicline in Ambivalent Smokers#888164
- Varenicline In-Patient Study#1086693
- A Study To Evaluate The Efficacy And Safety Of Varenicline Compared To Placebo For Smoking Cessation Through Reduction#875285
- Effect of Varenicline on Tobacco Addiction and on Abstinence-induced Cognitive Impairment#867529
Record · ID 1308628
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive